Immutep

Immutep is a clinical-stage biotech focused on harnessing the Lymphocyte Activation Gene-3 (LAG-3) pathway to modulate the immune system, with programs targeting both oncology and autoimmune diseases. Founded on the pioneering discovery of LAG-3 by its CSO, Dr. Frédéric Triebel, the company has built a diversified portfolio including first-in-class assets and out-licensed candidates. Its strategy combines internal development of lead programs like efti with strategic partnerships with companies such as Novartis, MSD, and Merck KGaA to accelerate clinical progress and maximize value.

A comprehensive LAG-3 immunotherapy platform featuring multiple therapeutic modalities: soluble LAG-3 protein (MHC Class II agonist) to activate antigen-presenting cells, antagonist antibodies to block LAG-3 on T cells, agonist antibodies to suppress T cells in autoimmunity, and depleting antibodies to eliminate pathogenic T cells.

Immutep faces competition from large pharma companies with LAG-3 blocking antibodies (e.g., BMS's approved relatlimab, Regeneron's fianlimab). Its key differentiation is its first-in-class MHC Class II agonist efti, which has a distinct mechanism from T-cell blockers, and its pioneering work on LAG-3 agonist antibodies for autoimmunity, where it aims for a first-mover advantage.